Pegfilgrastim biosimilar - Lupin
Alternative Names: Armlupeg; Lupifil-P; Pegfilgrastim - Lupin; pegfilgrastim-unneLatest Information Update: 22 Dec 2025
At a glance
- Originator Lupin
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Febrile neutropenia
Most Recent Events
- 04 Dec 2025 Pegfilgrastim biosimilar licensed to Valorum Biologics in USA
- 01 Dec 2025 Registered for Febrile neutropenia (Prevention, In adults, Adjunctive treatment, In the elderly) in USA (SC, Injection)
- 23 Aug 2024 Registered for Febrile neutropenia (Adjunctive treatment, In the elderly, Prevention, In adults) in Canada (SC)